Britain and America have agreed to a major trade agreement that will guarantee zero tariffs on UK medicine exports entering the American market.
The Terms of the Accord
As part of the deal, the UK has agreed to boost funding on medicines through the National Health Service (NHS). This pledge ensures that duties on these crucial products will stay at zero for a period of the next three years.
This agreement comes after previous threats to dramatically increase duties on patented pharmaceutical imports, with figures discussed as high as double the cost.
"This arrangement with the UK bolsters the worldwide climate for new treatments and establishes much-needed balance to transatlantic drug exports," a release noted.
Commercial Significance
Drugs represent one of the Britain's biggest exports to the America, which is clearly the largest market for large UK drugmakers.
Export figures reveal that in the year leading up to September, the UK exported drugs totaling over eleven billion pounds to the US. This amount represented 17.4% of total UK exports in that span.
"This deal protects jobs, increases funding and facilitates the UK to become a worldwide center for biotech and pharma," a government official commented.
Detailed UK Commitments
The deal entails several key pledges from the UK:
- Price Threshold Increase: The UK will raise the cost ceiling at which it considers new medicines to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to raise total public funding on medicines from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The sum pharmaceutical firms must pay back to the NHS to control costs will be restricted at 15%. In the past, repayments topped twenty percent.
Recent Tensions
The deal follows a protracted tension between the sector and the UK government over drug pricing and approval rates.
These tensions were heightened by claims that US customers were charged a premium for the identical medicines than patients in the UK and Europe.
In recent months, several significant pharmaceutical investments in the UK have been halted or scrapped, while major investments have been directed toward US facilities.
One official acknowledged that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a percentage of its overall budget over the last ten years.